SCHEMBL1738464

SCHEMBL1738464

Cc1[nH]c2c(COc3ccc(Cl)c(Cl)c3)nccc2c1C

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 4/20 0.38
MAOA P21397 8/20 0.38
MAPT P10636 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
POLB P06746 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SCN9A Q15858 1/20 0.36
MEN1 O00255 1/20 0.35
SLC26A4 O43511 1/20 0.35
KMT2A Q03164 1/20 0.35
MAOB P27338 1/20 0.35
AHR P35869 1/20 0.35
KDM4E B2RXH2 2/20 0.35
GRM5 P41594 1/20 0.34
CCR4 P51679 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1737740 0.86 CYP1A2 (0.40) DYRK1AMAOAMAPTCYP1A2CYP3A4
Hydrochloric Acid SCHEMBL1735317 0.85 CYP1A2 (0.39) DYRK1AMAOAMAPTCYP1A2CYP3A4
SCHEMBL1736292 0.83 LMNA (0.41) DYRK1AMAOAMAPTCYP1A2CYP3A4
SCHEMBL1736493 0.81 CYP1A2 (0.40) DYRK1AMAOAMAPTCYP1A2CYP3A4
SCHEMBL1736369 0.79 KDM5A (0.41) DYRK1AMAPTCYP1A2CYP3A4CYP2C9
SCHEMBL5808997 0.75 NPC1 (0.43) DYRK1AMAOAMAPTCYP1A2CYP3A4
SCHEMBL1737540 0.74 PTGDR2 (0.38) DYRK1AMAOAMAPTPOLBTDP1
SCHEMBL1736542 0.73 L3MBTL1 (0.41) DYRK1AMAPTCYP1A2CYP3A4CYP2C9
Hydrochloric Acid SCHEMBL1735398 0.73 PTGDR2 (0.37) DYRK1AMAOAMAPTPOLBTDP1
SCHEMBL1737474 0.72 DYRK1A (0.38) DYRK1AMAOAMAPTPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188114-B2 Pyrrolo[2,3-C]pyridine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2012-05-29 US disclosed
EP-1784404-B1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORP (KR) 2011-11-16 EP disclosed
US-20110263306-A1 COMPUTER SYSTEM AND PROGRAM NAMCO BANDAI GAMES INC. (JP) 2011-10-27 US disclosed
US-20100069430-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2010-03-18 US disclosed
US-7662832-B2 Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2010-02-16 US disclosed
EP-1784404-A4 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORP (KR) 2009-09-09 EP disclosed
US-20070219230-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2007-09-20 US disclosed
EP-1784404-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF Yuhan Corporation (KR) 2007-05-16 EP disclosed
WO-2006025716-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069430-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF PGA5, ATP6AP1, ATP6V1H DYRK1A 705/4885MAOA 2305/4885MAPT 3920/4885
US-20070219230-A1 PYRROLO[2,3-C]PYRIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF PGA5, ATP6AP1, ATP6V1H DYRK1A 705/4885MAOA 2305/4885MAPT 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.